Loading…
← CockpitCompetitor Analysis › LRMR Larimar Therapeutics, Inc.Open in the cockpit ↗

Larimar Therapeutics, Inc.LRMRCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum neutral 53
Mkt cap
$337M
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$3.58M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.7%
Hurdle
n/a
no reverse DCF
Next earnings
121 days
19 Mar 2027
Close · USD$3.23
1D+7.9%
1W+18.1%
1M+32.2%
3M-22.5%
6M-8.6%
YTD-15.3%
1Y-8.6%
ATR %8.4%
Beta1.93
52w lowhigh49.8% off high

What Larimar Therapeutics does

Employees: 71

Larimar Therapeutics at a glance

Size Larimar Therapeutics (LRMR) is a United States Health Care company (Biotechnology) with a market value of $337M, the 2978th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.23 on 18 Nov 2026.

Performance Over six months the shares fell 8.6%, against -31.0% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Short interest Short interest is 10.1% of the free float (30 Oct 2026).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026LRMR 90Peer median 69
Six months, rebased to 100: Larimar Therapeutics against the median of its 20 peers (local-currency closes).

Larimar Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$301,000-$350,000-$318,000-$311,000-$272,000
EBITDA-$179M-$172M-$90.6M-$41.4M-$36.3M
Net income-$173M-$166M-$80.6M-$36.9M-$35.4M
Free cash flow-$156M-$113M-$71.3M-$33.6M-$27.7M
Capital expenditure$153,000$91,000$515,000$164,000$100,000
Total debt$4.96M$4.07M$5.12M$5.55M$5.41M

Quarterly statements and history in the cockpit →

Larimar Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-80%-60%-40%-20%0%-25%0%+25%358570LYEL38802105086900CCCC69457630CRMDPROKCTNM476060NAUT4894XFORGLSIPRTCLRMR6-month return →1-month return →
Up and to the right = strong over both horizons. Larimar Therapeutics is the large dot.

Larimar Therapeutics competitors and peer comparison

How Larimar Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Larimar Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureLRMRPeer medianRank in peer set
1-month return+32.2%-4.7%2nd highest of 20
6-month return-8.6%-31.0%2nd highest of 20
Distance from 52-week high-49.8%-52.1%9th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%27.4×n/an/a

Questions

Which companies are Larimar Therapeutics's closest peers?
The cockpit's peer set: GI Innovation (358570.KS), Lyell Immunopharma (LYEL), Medtide (3880.HK), Aspen Neuroscience (ASPE), Laekna (2105.HK), Medy-Tox (086900.KS), C4 Therapeutics (CCCC), AP Biosciences (6945.TWO).
How has Larimar Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -8.6% against -31.0% for the median peer; over one year -8.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.